(MedPage Today) — A broad population of people with chronic obstructive pulmonary disease (COPD), current and former smokers alike, experienced fewer exacerbations taking a first-in-class biologic targeting interleukin (IL)-33, a pair of double…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
